Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kiadis Pharma has obtained a notice of patent allowance for its blood cancer treatment ATIR in the US.
Subscribe to our email newsletter
US patent protects various aspects of the cell-based product including rhodamine derivative’s composition of matter, vital steps involved in ATIR manufacturing process and therapeutic use of ATIR in preventing graft-versus-host disease connected with allogeneic stem cell transplantations.
Kiadis Pharma chief executive officer Manfred Ruediger said, "We are delighted about the broad patent protection for ATIR in the world’s largest pharmaceutical market. This broad patent protection provides a strong basis for future commercialization of ATIR to the benefit of patients."
The cell-based product facilitates stem cell transplantations from incompatible family donors to patients suffering from blood cancer.
ATIR previously obtained orphan drug designation in EU and the US.